Baidu
map

首批入营公布| HiMed-Biodesign医创营百特透析、重症专场持续招募中!

2021-09-28 网络 网络

现招募约40位早期医疗创新创业者加入HiMed-Biodesign医创营携手百特医疗推出的针对透析、重症、数字医疗专场医创加速课程。

 
HiMed-Biodesign医创营携手百特医疗重磅推出针对透析、重症、数字医疗专场医创加速课程,将于10月15日-16日正式启航!现招募约40位早期医疗创新创业者加入,以斯坦福Biodesign医疗科技创新理念,通过深度跨学科交流,医工结合、种子孵化,赋能加码医疗科技创新创业者,为行业发展增添新活力。期待您的加入! 

 

首批入营名单公布,第二批正在确认中,剩余名额有限,报名从速,先报先得~

*注:首批已短信通知,以上排名无先后顺序

 

本期医创营导师团队来自百特医学事务部研发部战略部及HiMed,导师分组带队、创意碰撞、实战路演。

 

图片

刘耀坤
泰莱生物CEO

超过40年医疗健康行业经验,拥有深厚的产业及商业经验。曾任默沙东、百特、先灵葆雅、中国生物制品有限公司、美诺医疗集团、贝诺国际等国际知名生物医疗企业的中国区总裁、董事等高层职位。现同时担任 Solasia Pharma K.K.(日本上市公司)和西安力邦制药独立董事。被誉为中国医疗健康行业“培养最多CEO的CEO”。

 

图片

宋成利
HiMed首席科学家
上海理工大学医疗器械与食品学院教授

教授,博导,东方学者。斯坦福Biodesign中文官方译者。2009年获聘上海市东方学者特聘教授,回国任职于上海理工大学医疗器械与食品学院。主要研究方向为微创医疗器械、智能材料和生物力学,所参与研制的胃肠吻合器、射频吻合器械等医疗器械产品获得美国FDA和欧洲CE认证。研究成果多次获得国际医学科技界的奖励,包括欧洲内镜外科学会(EAES)最佳论文奖,上海市科技进步三等奖和机械工业科技进步二等奖。成功孵化多个优秀医疗项目。

 

图片

赵卫国

博阳生物创始人CEO

科美诊断首席科学家

2005年创办博阳生物,并担任CEO职位。先后在美国洛约拉大学医学院,美国伊利诺伊大学学习,在美国杜邦诊断、德灵诊断总部工作近10年。是中国大陆留学生中第一个获得美国国家临床深化科学院会员资格,2003-2005年担任上海市检验医学重点实验室主任,上海交通大学教授,08年至今兼任上海核学会标记免疫专业委员会主任委员。

 

图片

张捷

HiMed医疗天使基金合伙人

HiMed发起人

HiMed医疗天使基金合伙人、HiMed发起人、前微创医疗常务副总裁。上海交通大学工学、经济学双学士,中欧国际工商学院EMBA。2010年开始投身天使医疗投资,在医疗投资领域有着丰富的经验和独特见解。所投资的公司均有不凡发展,包括纽脉医疗、逸思医疗、卓道医疗和福寿康康复护理机构等。2017年12月,创建了普健济康医创基地。曾获上海市科技创业领军人物,长三角创新精英人物十佳等称号。

 

图片

翟靖波
HiMed秘书长
衍禧堂孵化器创始人总经理

上海市科技创业导师,CPA,EMBA,RTTP。在早期医疗科技领域,拥有10多年孵化、服务、天使投资以及跨国项目落地咨询服务的丰富经验,投资孵化了上百个医疗早期项目,特别是在医疗器械、IVD、数字医疗等领域。2008年创办衍禧堂医疗孵化器,2014年发起HiMed社群,2015年成立HiMed医疗天使基金。迄今为止,衍禧HiMed孵化服务企业超300家,投资医创企业近40家。

 

图片

王肇龙
HiMed创新中心主任

首都医科大学临床医学学士,美国亚利桑那州立大学雷鸟商学院MBA。中国医学装备学会急救医学装备专业委员会委员,中国医疗器械行业协会医疗物联网专业委员会委员,前江苏省医疗器械行业协会副会长。20多年的医疗器械市场营销经验,曾在辉瑞、赛诺菲、强生、苏州法兰克曼担任销售总监及总经理等职务。

 

图片

张健
海脉德基金合伙人

上海意道医疗器械有限公司总经理,EMBA,供应链硕士学位。2010开始投身医疗器械领域创业。历任上海奥普生物医药副总,ALere (原 IMI) 中国区采购物流经理、朗讯等多家外企运营经理负责生产管理和新产品导入。熟悉企业运作和管理,对于新产品开发和项目管理有丰富的经验和见地,娴熟的海外合作和项目引进经验。在医疗领域先后投资20多家初创企业。

我们招募

招募领域

透析(腹膜透析、血液透析)

重症监护

数字医疗

 

面向人群

面向人群:发现临床需求,想把想法转化为技术的医生

有前沿技术,想把技术转化为产品的科研人员

有工程经验,想要创造创新产品的工程师

有市场资源,想要实现创业梦想的管理人员

有创业经验,想要打磨提升创业能力的创业者

 

晋级路径

2天必训 (40人,免费) 

理论授课,实战路演

 3个月加速营(40进5,价值10万)

40进5,Biodesign深度孵化

HiMed种子基金配套(10-50万)

金种子孵化计划

DemoDay路演(寻找天使人)

毕业路演

 

2天必训

22天必训

课程目标通过理论授课、创业模拟、实战路演,了解Biodesign医疗科技创新流程体系,感受创业氛围,碰撞创新思想。

 

图片

创业模拟

1.模拟组建创业团队,配齐组内创业人员要素,包括CEO、CTO、CMO至少3人;

2.根据小组方向配备师资,头脑风暴,碰撞创新Idea;

3.导师带领,分组讨论包括概念构思、产品设计、商业规划、项目计划等;

4.第二天实战路演,评委点评。

3个月加速营

3个月Biodesign课程,全流程科学孵化。

图片

 

发现需求 Identify(18课时)

1.发现与甄别:真实临床需求

2.研究与评估:疾病状态基础与已有方案

3.分析与需求筛选:利益相关者与市场分析

 

发明创造 Invent(18课时)

1.产品概念构思与头脑风暴

2.概念筛选与原型设计

3.原型测试与最终概念选择

 

发挥价值 Implement(18课时)

1.战略发展:知识产权/研发/医保/监管等

2.商业规划:营销战略与财务模型

3.商业计划书与融资培训

我要报名

活动流程

报名截至10月7日

学员招募&筛选(40人,择优入营)

最后一批确认 10月8日

分批确认,以短信通知为准

2天必训 10月15日-16日

授课地点:上海市张江科学城祥科路58号B栋5层

第一期加速营 11月4日

3个月加速营

*注:本次医创营如遇疫情等特殊情况,将酌情延期或做其他安排,具体以短信通知为准。

 

报名方式

扫描或识别下方二维码报名

图片

 

咨询联系人:

小   脉:19916567386(手机/微信)

Nancy:15618033086(手机/微信)

BP投递:BP@joyincenter.com

 

往期成果

图片
图片
图片
图片

HiMed-Biodesign医创营,目前已举办国内6期、国际4期医创营,200多位校友同盟,携手共进。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784172, encodeId=f3381e8417210, content=<a href='/topic/show?id=96d5586e14' target=_blank style='color:#2F92EE;'>#Design#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5867, encryptionId=96d5586e14, topicName=Design)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Nov 13 03:59:00 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919314, encodeId=adc119193141c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 05 11:59:00 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036220, encodeId=98c220362208c, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Oct 24 22:59:00 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558552, encodeId=c3511558552e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564561, encodeId=ede5156456137, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588481, encodeId=f47f1588481f4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611265, encodeId=3801161126575, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1784172, encodeId=f3381e8417210, content=<a href='/topic/show?id=96d5586e14' target=_blank style='color:#2F92EE;'>#Design#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5867, encryptionId=96d5586e14, topicName=Design)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Nov 13 03:59:00 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919314, encodeId=adc119193141c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 05 11:59:00 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036220, encodeId=98c220362208c, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Oct 24 22:59:00 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558552, encodeId=c3511558552e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564561, encodeId=ede5156456137, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588481, encodeId=f47f1588481f4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611265, encodeId=3801161126575, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2022-07-05 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1784172, encodeId=f3381e8417210, content=<a href='/topic/show?id=96d5586e14' target=_blank style='color:#2F92EE;'>#Design#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5867, encryptionId=96d5586e14, topicName=Design)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Nov 13 03:59:00 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919314, encodeId=adc119193141c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 05 11:59:00 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036220, encodeId=98c220362208c, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Oct 24 22:59:00 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558552, encodeId=c3511558552e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564561, encodeId=ede5156456137, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588481, encodeId=f47f1588481f4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611265, encodeId=3801161126575, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-10-24 爆笑小医
  4. [GetPortalCommentsPageByObjectIdResponse(id=1784172, encodeId=f3381e8417210, content=<a href='/topic/show?id=96d5586e14' target=_blank style='color:#2F92EE;'>#Design#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5867, encryptionId=96d5586e14, topicName=Design)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Nov 13 03:59:00 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919314, encodeId=adc119193141c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 05 11:59:00 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036220, encodeId=98c220362208c, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Oct 24 22:59:00 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558552, encodeId=c3511558552e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564561, encodeId=ede5156456137, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588481, encodeId=f47f1588481f4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611265, encodeId=3801161126575, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1784172, encodeId=f3381e8417210, content=<a href='/topic/show?id=96d5586e14' target=_blank style='color:#2F92EE;'>#Design#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5867, encryptionId=96d5586e14, topicName=Design)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Nov 13 03:59:00 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919314, encodeId=adc119193141c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 05 11:59:00 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036220, encodeId=98c220362208c, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Oct 24 22:59:00 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558552, encodeId=c3511558552e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564561, encodeId=ede5156456137, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588481, encodeId=f47f1588481f4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611265, encodeId=3801161126575, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-09-30 fusion
  6. [GetPortalCommentsPageByObjectIdResponse(id=1784172, encodeId=f3381e8417210, content=<a href='/topic/show?id=96d5586e14' target=_blank style='color:#2F92EE;'>#Design#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5867, encryptionId=96d5586e14, topicName=Design)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Nov 13 03:59:00 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919314, encodeId=adc119193141c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 05 11:59:00 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036220, encodeId=98c220362208c, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Oct 24 22:59:00 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558552, encodeId=c3511558552e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564561, encodeId=ede5156456137, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588481, encodeId=f47f1588481f4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611265, encodeId=3801161126575, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-09-30 fusion
  7. [GetPortalCommentsPageByObjectIdResponse(id=1784172, encodeId=f3381e8417210, content=<a href='/topic/show?id=96d5586e14' target=_blank style='color:#2F92EE;'>#Design#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5867, encryptionId=96d5586e14, topicName=Design)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Nov 13 03:59:00 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919314, encodeId=adc119193141c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 05 11:59:00 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036220, encodeId=98c220362208c, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Oct 24 22:59:00 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558552, encodeId=c3511558552e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564561, encodeId=ede5156456137, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588481, encodeId=f47f1588481f4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611265, encodeId=3801161126575, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-09-30 skhzy
  8. [GetPortalCommentsPageByObjectIdResponse(id=1784172, encodeId=f3381e8417210, content=<a href='/topic/show?id=96d5586e14' target=_blank style='color:#2F92EE;'>#Design#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5867, encryptionId=96d5586e14, topicName=Design)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Nov 13 03:59:00 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919314, encodeId=adc119193141c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jul 05 11:59:00 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036220, encodeId=98c220362208c, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Oct 24 22:59:00 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558552, encodeId=c3511558552e6, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564561, encodeId=ede5156456137, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588481, encodeId=f47f1588481f4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611265, encodeId=3801161126575, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 30 07:59:00 CST 2021, time=2021-09-30, status=1, ipAttribution=)]

相关资讯

Keytruda中国临床试验招募患者:非小细胞肺癌

Keytruda中国临床试验招募患者

招募患者:Nivolumab注射液治疗晚期或转移性非小细胞肺癌的临床试验

一、题目和背景信息  登记号: CTR20150767  适应症: 晚期或转移性非小细胞肺癌  试验通俗题目: 对复发的晚期或转移性非小细胞肺癌的研究  试验专业

人贩贴:梅斯医学招募高级医学兼职编辑啦!

梅斯医学招募高级医学兼职编辑啦!快来看看吧!边学习边做兼职,一种新鲜一种挑战!招募对象有一定文字撰写能力的医生、医学生、临床医生等工作内容:1,SCI文献指南共识解读;2,根据医学文献或会议内容进行软文撰写;3,专家幻灯整理;职位要求:1,学历、专业:本科以上,临床医学或药学;2,有医院临床工作经验者优先;3,熟悉office办公软件操作,尤其是PPT和Word;4,熟悉医学文章撰写要求,有专业的

招募患者:PD-1抗体(BMS-936558)在中国晚期或复发性实体瘤受试者中的I、II期、开放性临床研究

1. 试验药物简介 PD-1抗体(programmed death 1)程序性死亡受体1,是一种重要的免疫抑制分子。本试验药物是百时美施贵宝(BMS)研发的Nivolumab。 本试验的适应症是晚期或复发性实体瘤的中国受试者(包括但不限于非小细胞肺癌、胃癌、鼻咽癌、食管癌)。 2. 试验目的 本研究的目的是评估nivolumab治疗中国晚期或复发性实体瘤受试者的安全性和疗

PDL-1和CTLA-4招募晚期尿路上皮癌患者

PDL-1和CTLA-4招募晚期尿路上皮癌患者

正在招募患者:晚期癌症、乳腺癌、强直性脊柱炎、顽固性高血压大汇集

分享一次意味着让这些痛苦的患者有一次新药治疗的机会!临床试验是推动人类健康事业向前发展的重要手段,参加新药研究,可以使患者最早受益于这些新药的治疗,可能获得好的治疗,尤其对于复发难治的患者,目前已经上市的药物没有好的治疗效果时,临床试验新药是首选治疗。【梅斯医学-患者招募】已建立临床试验推荐中心,目前已有多种相关药物临床试验,覆盖心血管、肿瘤、内分泌、骨科等领域。愿意与广大临床医生、以及药企和CR

Baidu
map
Baidu
map
Baidu
map